A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

@article{Shah2010AMP,
  title={A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma},
  author={Manish A. Shah and Derek G. Power and Hedy L. Kindler and Kyle D. Holen and Margaret M. Kemeny and David H. Ilson and Laura Tang and Marinela Capanu and John J. Wright and David P. Kelsen},
  journal={Investigational New Drugs},
  year={2010},
  volume={29},
  pages={1475-1481}
}
SummaryPurpose The transcription factor nuclear factor-kB (NFkB) is implicated in gastric cancer carcinogenesis and survival, and its inhibition by proteosome inhibition is associated with preclinical gastric cancer anti-tumor activity. We examined the single agent efficacy of bortezomib, a selective proteasome inhibitor, in gastric adenocarcinoma. Experimental Design We performed a phase II trial of bortezomib in patients with advanced gastric adenocarcinoma. Bortezomib 1.3 mg/m2 was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2015
VIEW 1 EXCERPT
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES